Drug intelligence / Profile preview

tp-38

Development stage
Phase 2
Lead developer
Avid Bioservices
Modality
Recombinant Proteins and Enzymes, Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics
Administration
Intracerebral Infusion
01

Overview

TP-38 is an investigational immunotoxin designed for the treatment of brain tumors, particularly gliomas. It consists of a recombinant fusion protein that combines a targeting ligand (epidermal growth factor, EGF) with a modified Pseudomonas exotoxin A. The EGF component binds specifically to the epidermal growth factor receptor (EGFR), which is overexpressed on many tumor cells, including glioblastoma multiforme. Upon binding to EGFR-expressing tumor cells, TP-38 is internalized and delivers the exotoxin into the cell, leading to inhibition of protein synthesis and subsequent cell death. This targeted approach aims to kill tumor cells while sparing normal tissue[1][2][4].

Brand names
Cervene
Other names
TP-38 immunotoxinTP38 immunotoxinTP 38 immunotoxinTP-38 toxinTP38 toxinTP 38 toxin
02

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)EEF2 (Eukaryotic elongation factor 2)

Beyond the preview

Go deeper on tp-38.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on tp-38.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call